Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortizatization of Intangibles (2016 - 2025)

Ligand Pharmaceuticals' Amortizatization of Intangibles history spans 11 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 232.51% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $5.0 million, up 272.5%, while the annual FY2025 figure was $5.0 million, 272.5% up from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $2.0 million at Ligand Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.0 million in Q4 2025 and bottomed at -$150000.0 in Q1 2021.
  • The 5-year median for Amortizatization of Intangibles is $218000.0 (2023), against an average of $374000.0.
  • The largest annual shift saw Amortizatization of Intangibles crashed 82.93% in 2022 before it skyrocketed 5285.71% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $34000.0 in 2021, then surged by 73.53% to $59000.0 in 2022, then soared by 544.07% to $380000.0 in 2023, then soared by 59.47% to $606000.0 in 2024, then surged by 232.51% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Amortizatization of Intangibles are $2.0 million (Q4 2025), $1.3 million (Q3 2025), and $766000.0 (Q2 2025).